JP2020525021A - 損傷および／または老化細胞の同定および排除 - Google Patents

損傷および／または老化細胞の同定および排除 Download PDF

Info

Publication number
JP2020525021A
JP2020525021A JP2019572038A JP2019572038A JP2020525021A JP 2020525021 A JP2020525021 A JP 2020525021A JP 2019572038 A JP2019572038 A JP 2019572038A JP 2019572038 A JP2019572038 A JP 2019572038A JP 2020525021 A JP2020525021 A JP 2020525021A
Authority
JP
Japan
Prior art keywords
damaged
cells
senescent cells
antagonist
interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019572038A
Other languages
English (en)
Japanese (ja)
Inventor
セラーノ マルガン マニュエル
セラーノ マルガン マニュエル
ラノス ギロン スサナ
ラノス ギロン スサナ
セリム チャイブ アンディ
セリム チャイブ アンディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro Nacional de Investigaciones Oncologicas CNIO
Original Assignee
Centro Nacional de Investigaciones Oncologicas CNIO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Nacional de Investigaciones Oncologicas CNIO filed Critical Centro Nacional de Investigaciones Oncologicas CNIO
Publication of JP2020525021A publication Critical patent/JP2020525021A/ja
Priority to JP2023061595A priority Critical patent/JP2023098947A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019572038A 2017-06-29 2018-06-29 損傷および／または老化細胞の同定および排除 Pending JP2020525021A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023061595A JP2023098947A (ja) 2017-06-29 2023-04-05 損傷および／または老化細胞の同定および排除

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382417.8 2017-06-29
EP17382417.8A EP3421607A1 (en) 2017-06-29 2017-06-29 Identification and elimination of damaged and/or senescent cells
PCT/EP2018/067655 WO2019002581A1 (en) 2017-06-29 2018-06-29 IDENTIFICATION AND ELIMINATION OF DAMAGED AND / OR SENESCENT CELLS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023061595A Division JP2023098947A (ja) 2017-06-29 2023-04-05 損傷および／または老化細胞の同定および排除

Publications (1)

Publication Number Publication Date
JP2020525021A true JP2020525021A (ja) 2020-08-27

Family

ID=59315550

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019572038A Pending JP2020525021A (ja) 2017-06-29 2018-06-29 損傷および／または老化細胞の同定および排除
JP2023061595A Pending JP2023098947A (ja) 2017-06-29 2023-04-05 損傷および／または老化細胞の同定および排除

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023061595A Pending JP2023098947A (ja) 2017-06-29 2023-04-05 損傷および／または老化細胞の同定および排除

Country Status (5)

Country Link
US (2) US20200123607A1 (enExample)
EP (2) EP3421607A1 (enExample)
JP (2) JP2020525021A (enExample)
CA (1) CA3068363A1 (enExample)
WO (1) WO2019002581A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023238845A1 (ja) * 2022-06-07 2023-12-14 アステラス製薬株式会社 加齢疾患の治療又は予防のための抗インテグリンα１１抗体を含む医薬組成物
WO2024063109A1 (ja) * 2022-09-20 2024-03-28 国立大学法人東京大学 老化細胞除去剤

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7407822B2 (ja) 2018-08-30 2024-01-04 エイチシーダブリュー バイオロジックス インコーポレイテッド 単鎖キメラポリペプチドおよびその使用
CA3108949A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2020257639A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
US12187763B2 (en) 2020-02-11 2025-01-07 Immunitybio, Inc. Chromatography resin and uses thereof
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
WO2021163369A2 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
JP7734693B2 (ja) 2020-04-29 2025-09-05 イミュニティーバイオ インコーポレイテッド 抗ｃｄ２６タンパク質及びそれらの使用法
US12024545B2 (en) * 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
EP4431102A4 (en) * 2021-11-10 2025-10-29 Lifeceutix Co Ltd Senescent Cell Elimination Compositions and Their Uses
CN114836508A (zh) * 2021-12-08 2022-08-02 上海锐翌医学检验实验室有限公司 慢性阻塞性肺病标志微生物及其应用
KR20240155337A (ko) 2022-03-04 2024-10-28 리주베론 세네센스 테라퓨틱스 아게 항-pd-l2 항체
CN115154611B (zh) * 2022-06-23 2023-11-17 中山大学孙逸仙纪念医院 免疫检查点抑制剂与抗衰老药物联合在制备肿瘤治疗产品中的用途
WO2024228599A1 (ko) * 2023-05-04 2024-11-07 주식회사 라이프신약 노화세포 제거 또는 억제용 조성물 및 이의 용도
WO2024249938A1 (en) * 2023-05-31 2024-12-05 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating senescence/age-related diseases
WO2025051889A1 (en) * 2023-09-06 2025-03-13 Rejuveron Senescence Therapeutics Ag Anti pd-l2 antibodies for use in treating fibrotic diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501624A (ja) * 2000-06-28 2004-01-22 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用
WO2016176504A1 (en) * 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
WO2016207646A1 (en) * 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
WO2017053250A1 (en) * 2015-09-21 2017-03-30 Merck Sharp & Dohme Corp. Antibody that binds to human programmed death ligand 2 (pd-l2) and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU2005248958A1 (en) * 2000-06-28 2006-02-02 Brigham And Women's Hospital PD-L2 molecules: novel PD-1 ligands and uses therefor
JP2017508785A (ja) * 2014-02-04 2017-03-30 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ 癌を治療するためのｐｄ−１アンタゴニストおよびｉｄｏ１阻害剤の組み合わせ
WO2016134416A1 (en) * 2015-02-23 2016-09-01 The University Of Queensland A method for assessing prognosis of lymphoma

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501624A (ja) * 2000-06-28 2004-01-22 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用
WO2016176504A1 (en) * 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
WO2016207646A1 (en) * 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
WO2017053250A1 (en) * 2015-09-21 2017-03-30 Merck Sharp & Dohme Corp. Antibody that binds to human programmed death ligand 2 (pd-l2) and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.VIROL.(2007)VOL.81, NO.17, P.9249-9258, JPN6022017546, ISSN: 0005273527 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023238845A1 (ja) * 2022-06-07 2023-12-14 アステラス製薬株式会社 加齢疾患の治療又は予防のための抗インテグリンα１１抗体を含む医薬組成物
WO2024063109A1 (ja) * 2022-09-20 2024-03-28 国立大学法人東京大学 老化細胞除去剤

Also Published As

Publication number Publication date
CA3068363A1 (en) 2019-01-03
US20200123607A1 (en) 2020-04-23
EP3645746A1 (en) 2020-05-06
WO2019002581A1 (en) 2019-01-03
EP3421607A1 (en) 2019-01-02
US20240344128A1 (en) 2024-10-17
JP2023098947A (ja) 2023-07-11

Similar Documents

Publication Publication Date Title
US20240344128A1 (en) Identification and elimination of damaged and/or senescent cells
RU2579897C2 (ru) Агенты, связывающие рецептор "frizzled", и их применение
JP6564408B2 (ja) Ｓ１００ａ４抗体およびその治療上の使用
KR20200119834A (ko) 항-cd47 및 항-cd20 항체를 이용한 항암 섭생
AU2017373819A1 (en) Antibodies and polypeptides directed against CD127
KR20140024914A (ko) 예측인자로 세레브론을 사용하는 암 및 염증성 질환의 치료를 위한 방법
US20170246298A1 (en) Methods and compositions for cancer treatment and treatment selection
JP6316498B2 (ja) Ｃｋａｐ４を標的分子とした抗腫瘍剤
US12173042B2 (en) Methods of treating cancers with CT45 targeted therapies
EP3773658A1 (en) Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof
TW201023852A (en) Cancer therapy
CA3078430A1 (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
WO2016073299A1 (en) Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses
CN110582303A (zh) 使用抗cd25抗体-药物缀合物的组合疗法
CN116209461A (zh) Cd-30阳性癌症的治疗
JP2012522728A (ja) セマフォリン３ｃ（ｓｅｍａ３ｃ）阻害治療剤、方法及び用途
CN114340659B (zh) 联合治疗
US20230287415A1 (en) Combined therapy against cancer
WO2020061381A1 (en) Ptprs and proteoglycans in rheumatoid arthritis
WO2020071554A1 (ja) がん幹細胞特異的抗体
WO2008046529A1 (en) Treatment of chemotherapy- or radiotherapy-resistant tumors using an l1 interfering molecule
JP2023553247A (ja) がん診断のための組成物および方法
WO2008068481A1 (en) New compounds, methods and uses
WO2023104910A1 (en) Treatment of lymphoma
WO2008046459A1 (en) Treatment of chemotherapy- or radiotherapy-resistant tumors using an l1 interfering molecule

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210618

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230405

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230406

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230424

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240308